RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

DNA Funded vs Savius

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

DNAF

DNA Funded

SVUS

Savius

EST. 2013

DNA FUNDED

METRIC

SAVIUS

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

90%

—

MAX FUNDING

$300,000

—

MIN COST

$285

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

DNA FUNDED DETAILS

STEPS: -phase

SAVIUS DETAILS

STEPS: 1-phase
DRAWDOWN: Fixed
MARKETS: Futures, Indices
PLATFORMS: ATAS, Quantower

DNA Funded PROS

+No performance data is available to identify any above-average metrics for this firm
+No fee, payout, or structure data provided to evaluate competitiveness
+No platform or market data available to assess trading flexibility
+Country of operation (Australia) is noted, but no regulatory or structural data exists

DNA Funded CONS

−No data is provided for this firm, making any meaningful comparison impossible
−Traders cannot assess profit split, funding, or costs against the 84.7% and $186.7 averages
−Complete absence of data is a significant transparency concern for traders making financial decisions

Savius PROS

+Profit split of 90% exceeds the industry average of 84.7% by 5.3 percentage points
+Days to first payout is 3, significantly faster than the industry average of 6.5 days
+Steps to funded is 1, well below the industry average of 1.6, simplifying the path to capital
+Founded in 2013, making it one of the more established prop firms with over a decade of operation

Savius CONS

−Max funding of $300,000 is well below the industry average of $839,272, limiting earning potential
−Min challenge cost of $285 is significantly higher than the industry average of $186.70
−Overall drawdown of 4% is considerably tighter than the industry average of 7.9%, increasing risk of disqualification

PROPDNA VERDICT

DNA Funded

Higher trust score (0/100). Slower payouts at —d.

START WITH DNAF